Open AccessLong‐Term Effects of Repeated Cycles of Intrathecal Triamcinolone Acetonide on Spasticity in MS Patients
Author(s) -
Rommer Paulus Stefan,
Kamin Frank,
AbuMugheisib Mazen,
Koehler Wolfgang,
Hoffmann Frank,
Winkelmann Alexander,
Benecke Reiner,
Zettl Uwe Klaus
Publication year - 2016
Publication title -
cns neuroscience and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 69
eISSN - 1755-5949
pISSN - 1755-5930
DOI - 10.1111/cns.12474
Subject(s) - spasticity , medicine , multiple sclerosis , repeated measures design , anesthesia , quality of life (healthcare) , intrathecal , nursing , psychiatry , statistics , mathematics
Summary Main problem Spasticity is a common feature in patients with multiple sclerosis ( MS ). Although options have broadened over the last years, there are still patients with no response to common therapeutic agents. Intrathecal administered triamcinolone acetonide ( TCA ) has been tested for spasticity in patients with MS . However, the long run effects are not known so far. The aim of this study was to evaluate the effects of repeated cycles of intrathecal TCA instillations on clinical parameters. Methods A total of 54 patients with clinically definite MS and no response to commonly utilized antispastic drugs were enrolled. TCA was administered every 3 months for a period of 9 months. Clinical assessments including spasticity, disability ( EDSS ), mobility (walking distance, and timed 25‐foot walk), bladder function, and quality of life were carried out prior to and at the end of each treatment cycle. Results Repeated TCA treatment led to repeated effects on spasticity ( P < 0.01). Bladder function improved in every 10th patient. Quality of life improved during each cycle but did not reach significance at the end of study ( P = 0.09). However, long‐lasting improvement on spasticity or EDSS was not shown at end of the study. Effects diminished over 3 months. Conclusion Repeated TCA instillations led to replicable effects on spasticity; subgroup analyses suggest that higher spasticity, more frequent treatments, and higher EDSS may lead to pronounced effects on spasticity and EDSS . Intrathecal TCA treatment was safe and no severe side effects occurred. We hypothesize a significant time dependence of re‐administration of TCA and that an interval of 3 months between the treatments might be too long.